JASPI

Medical Antimicrobial Prophylaxis in Indian Settings – What to Practice Prasan Kumar Panda*  Vinay Tulsian JASPI June 2025 / Volume 3/Issue 2 Copyright: © Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source […]

NARRATIVE REVIEW Medical Antimicrobial Prophylaxis in Indian Settings – What to Practice Prasan Kumar Panda*  Vinay Tulsian JASPI June 2025 / Volume 3/Issue 2 Copyright: © Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author

Other specific DSP article suggested by Editorial Board From access to reserve: antimicrobial resistance among etiological agents of central line-associated bloodstream infections in the view of WHO’s AWaRe antimicrobial spectrum. DOI: 10.3205/dgkh000559 Authors:Anand G et al   Abstract   Aim: Central line-associated bloodstream infections (CLABSI) remain a major contributor to morbidity and mortality in critically ill patients. The rise

Other specific DSP article suggested by Editorial Board Ventilator-associated pneumonia: how long is long enough? DOI: 10.1097/MCC.0000000000001298 Authors:Koulenti D et al   Abstract   Purpose of review: To provide an updated overview of optimal antibiotic duration in ventilator-associated pneumonia (VAP), integrating guideline recommendations, clinical evidence, and expert opinion.  Recent findings: A randomized controlled trial, retrospective studies

Global Preparedness for Clinical Research in Emerging Infections: Lessons from ISARIC’s Data-Driven Covid-19 Response Esteban Garcia-Gallo1*, Tom Edinburgh, Sara Duque Vallejo, Dhruv Darji, Barbara Wanjiru Citarella, Luis Felipe Reyes, Elise Pesonel, Laura Merson JASPI June 2025 / Volume 3 /Issue 2 Copyright: © Author(s). This is an open-access article distributed under the terms of the

Other specific DSP article suggested by Editorial Board Use of Daptomycin to Manage Severe MRSA Infections in Humans. DOI: 10.3390/antibiotics14060617 Authors: Fiore M et al   Abstract   Methicillin-resistant Staphylococcus aureus (MRSA) represents a major therapeutic challenge due to its multidrug-resistance and the associated clinical burden. Daptomycin (DAP), a cyclic lipopeptide antibiotic, has become a key agent

Volume 3 | Issue 2 | April-June 2025 ________________CONTENT__________________ Editorial Global Preparedness for Clinical Research in Emerging Infections: Lessons from ISARIC’s Data-Driven COVID-19 Response Esteban Garcia-Gallo*, Tom Edinburgh , Sara Duque Vallejo , Dhruv Darji, Barbara Wanjiru Citarella, Luis Felipe Reyes, Elise Pesonel, Laura Merson [PDF]         [FULL TEXT] Original Article Economic Impact of

Other specific DSP article suggested by Editorial Board Understanding antimicrobial resistance (AMR) mechanisms and advancements in AMR diagnostics. DOI: 10.1016/j.diagmicrobio.2025.116949 Authors: Sinha S et al   Abstract   The overuse and abuse of antibiotics, which results in the evolution of resistant microorganisms, is the primary cause of the global health catastrophe known as antimicrobial resistance (AMR). The

Practical considerations for the Implementation of Syndromic Panels and Diagnostic stewardship in the era of syndromic panel testing DOI: 10.1016/j.cmi.2025.06.013 Authors: Subedi S et al   Abstract Background: The significant advancements in the development of syndromic panel testing for infectious diseases have brought about a paradigm shift in the clinical microbiology laboratory and the practices of

Other specific DSP article suggested by Editorial Board A pre-post quasi-experimental study of antimicrobial stewardship exploring the impact of a multidisciplinary approach aimed at attaining an aggressive joint pharmacokinetic/pharmacodynamic target with ceftazidime/avibactam on treatment outcome of KPC-producing Klebsiella pneumoniae infections and on ceftazidime/avibactam resistance development. DOI: 10.1128/aac.00488-25 Authors: Gatti M et al   Abstract   To assess the